Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Vanda Pharmaceuticals Inc. (VNDA) vs X4 Pharmaceuticals, Inc. (XFOR)

Vanda Pharmaceuticals Inc. and X4 Pharmaceuticals, Inc. are both Biotechnology companies. Vanda Pharmaceuticals Inc. and X4 Pharmaceuticals, Inc. are of similar size ($301.1M and $297.4M). Vanda Pharmaceuticals Inc. grew revenue faster over the last twelve months: 6.02% against −51.7%. Vanda Pharmaceuticals Inc. has the higher net margin (−127.4% vs −568.8%) and the higher return on invested capital (−217.6% vs −226.6%). Across the 17 metrics below, Vanda Pharmaceuticals Inc. leads on 12 and X4 Pharmaceuticals, Inc. on 5.

Valuation

Metric VNDA XFOR Biotechnology median
P/E n/m n/m 7.88
P/S 1.42 24.00 11.47
P/B 1.39 2.45 2.52
Price to free cash flow n/m 23.86 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 0.64 15.77 10.73
Earnings yield (91.32%) (39.87%) (28.84%)
Free cash flow yield (50.11%) 4.19% (23.03%)

Profitability

Metric VNDA XFOR Biotechnology median
Gross margin 93.74% 81.51% 65.16%
Operating margin (86.07%) (554.71%) 0.00%
Net margin (127.41%) (568.80%) 0.00%
Free cash flow margin (70.93%) (559.95%) 0.00%
Return on equity (77.81%) (113.08%) (57.72%)
Return on assets (53.00%) (50.32%) (49.22%)
Return on invested capital (217.59%) (226.62%) 0.00%

Growth

Metric VNDA XFOR Biotechnology median
Revenue growth (TTM) 6.02% (51.65%) 5.64%
EPS growth (last fiscal year) (1,033.33%) 67.23% —
Revenue growth, 5-year CAGR (2.73%) — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric VNDA XFOR Biotechnology median
Debt to equity 0.01 0.49 0.00
Current ratio 1.61 11.30 4.73
Net debt to EBITDA 1.84 2.06 0.96

Dividend

Metric VNDA XFOR Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric VNDA XFOR Biotechnology median
Market cap 301.10m 297.44m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack